Related Experiment Video
Updated: May 24, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Stopping cancer in its tracks: using small molecular inhibitors to target glioblastoma migrating cells
Austin K Mattox1, Jing Li, David C Adamson
1Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University, Durham, NC 27710, USA.
Abstract:
Glioblastoma multiforme (GBM) represents one of the most common aggressive types of primary brain tumors. Despite advances in surgical resection, novel neuroimaging procedures, and the most recent adjuvant radiotherapy and chemotherapy, the median survival after diagnosis is about 12-14 months. Targeting migrating GBM cells is a key research strategy in the fight against this devastating cancer. Though the vast majority of the primary tumor focus can be surgically resected, these migrating cells are responsible for its universal recurrence. Numerous strategies and technologies are being explored to target migrating glioma cells, with small molecular inhibitors as one of the most commonly studied. Small molecule inhibitors, such as protein kinase inhibitors, phosphorylation site inhibitors, protease inhibitors, and antisense oligonucleotides show promise in slowing the progression of this disease. A better understanding of these small molecule inhibitors and how they target various extra- and intracellular signaling pathways may eventually lead to a cure for GBM.
Insights
Targeting migrating glioblastoma cells is crucial for treating this aggressive brain cancer. Small molecule inhibitors show promise in slowing disease progression and may lead to a cure.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer research
Background:
- Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with a poor prognosis.
- Current treatments (surgery, radiotherapy, chemotherapy) offer limited survival benefits (12-14 months).
- Recurrence is driven by migrating GBM cells, making them a key therapeutic target.
Purpose of the Study:
- To review strategies targeting migrating glioblastoma cells.
- To highlight the potential of small molecule inhibitors in GBM treatment.
- To understand the role of molecular pathways in GBM progression.
Main Methods:
- Review of current research on glioblastoma treatment strategies.
- Analysis of small molecule inhibitors targeting GBM.
- Exploration of extra- and intracellular signaling pathways involved in GBM migration.
Main Results:
- Small molecule inhibitors, including kinase, protease, and antisense inhibitors, show promise.
- These inhibitors target various signaling pathways crucial for GBM cell migration and survival.
- Targeting migrating cells is essential for preventing tumor recurrence.
Conclusions:
- Small molecule inhibitors represent a promising therapeutic avenue for glioblastoma.
- Further understanding of molecular pathways targeted by these inhibitors is needed.
- Developing effective strategies against migrating GBM cells could lead to improved patient outcomes and potentially a cure.
